rhamnosus , which provides invaluable GI tract protection for travelers
It is not a drug, is not approved for human or veterinary use, and should be handled only within a controlled research environment
Common injection sites include the abdomen, thigh, or upper arm
The most common adverse effects are mild gastrointestinal symptoms (nausea, vomiting, diarrhea) that typically occur at rates similar to placebo in controlled trials
and preparation, review, or approval of the manuscript
Metabolic improvements: Blood pressure, waist circumference, lipid profiles, and HbA1c all improved alongside weight reduction